Invizius has announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard® technology.
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target
Calculus has delivered an average ROI of 2.1x from Genedrive plc (AIM: GDR) through a number of exits in the VCT and EIS Funds. Genedrive, a company we had supported through scale-up, was founded as a contract research business (”CRO”) but refocussed as a Point of Care molecular diagnostics company. The company has developed and launched … Continued
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that it has raised £3.2 million
Calculus portfolio company Wonderhood Studios will be working with MADE to help creatively bring to life the brand’s vision, giving it a fresh and bold point of view
Welcome to our first update of 2022. The run up to the tax year end is always a busy time and this year has been no different. Our investment team has completed two exits, three investments and are building up a considerable pipeline for Q2. As popularity for VCTs across the board has continued to … Continued
Calculus VCT has invested into Destiny Pharma, a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.